Tiagabine

Tiagabine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Tiagabine is {{{aOrAn}}} anticonvulsant, gamma aminobutyric acid Uptake Inhibitor that is FDA approved for the treatment of partial seizures in adults and children > 12 years. Common adverse reactions include Pruritus (2% ) Gastrointestinal: Abdominal pain (5% to 7% ), Nausea (11% ) Neurologic: Asthenia (18% to 23% ), Ataxia (5% to 9% ), Confusion (5% ), Disturbance in speech (4% ), Dizziness (27 to 31% ), Feeling nervous (10% to 14% ), Insomnia (5% to 6% ), Somnolence (18% to 21% ), Tremor (9% to 21% ), Unable to concentrate (6% to 14% ) Respiratory: Pharyngitis (7% to 8% ).

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Tiagabine FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Tiagabine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Tiagabine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Tiagabine FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Tiagabine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Tiagabine in pediatric patients.

Contraindications

There is limited information regarding Tiagabine Contraindications in the drug label.

Warnings

There is limited information regarding Tiagabine Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Tiagabine Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Tiagabine Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Tiagabine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Tiagabine in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Tiagabine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Tiagabine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Tiagabine in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Tiagabine in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Tiagabine in geriatric settings.

Gender

There is no FDA guidance on the use of Tiagabine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Tiagabine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Tiagabine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Tiagabine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Tiagabine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Tiagabine in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Tiagabine Administration in the drug label.

Monitoring

There is limited information regarding Tiagabine Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Tiagabine and IV administrations.

Overdosage

There is limited information regarding Tiagabine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Tiagabine Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Tiagabine Mechanism of Action in the drug label.

Structure

There is limited information regarding Tiagabine Structure in the drug label.

Pharmacodynamics

There is limited information regarding Tiagabine Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Tiagabine Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Tiagabine Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Tiagabine Clinical Studies in the drug label.

How Supplied

There is limited information regarding Tiagabine How Supplied in the drug label.

Storage

There is limited information regarding Tiagabine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Tiagabine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Tiagabine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Tiagabine Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Tiagabine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Tiagabine Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Tiagabine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Tiagabine

File:Tiagabine.svg
Clinical data
Pregnancy category	B3 (Au), C (U.S.)
Routes of administration	Oral
ATC code	N03AG06 (WHO)
Legal status
Legal status	POM (UK), ℞-only (U.S.)
Pharmacokinetic data
Bioavailability	90%
Protein binding	96%
Metabolism	Hepatic (CYP450 system)
Elimination half-life	7-9 hours
Excretion	Fecal and renal
Identifiers
IUPAC name (3S)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl] piperidine-3-carboxylic acid
CAS Number	115103-54-3
PubChem CID	60648
DrugBank	APRD00344
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H25NO2S2
Molar mass	375.55 g/mol

Tiagabine (IPA: Template:IPA) is an anti-convulsive medication produced by Cephalon Inc. and marketed under the brand name Gabitril. The medication is also used in the treatment for panic disorder as are a few other anticonvulsants.

Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.

Side effects

Tiagabine's most common side effects include confusion, difficulty speaking clearly/stuttering, mild sedation, and in doses over 8 mg, a tingling sensation (paraphasia) in the body's extremities, particularly the hands and fingers.

External links

• Gabitril (manufacturer's website)